Roche to acquire 89bio, will get pegozafermin for MASH in deal
As part of a merger deal, Roche will acquire 89bio and its treatment candidate pegozafermin — an injection therapy now being tested in two global…
As part of a merger deal, Roche will acquire 89bio and its treatment candidate pegozafermin — an injection therapy now being tested in two global…
Nesfatin-1 (NF-1), a hormone-like molecule that may ease cellular stress, reduced injury to the placenta in a mouse model of intrahepatic cholestasis of pregnancy…
The U.S. Food and Drug Administration (FDA) has granted orphan drug and rare pediatric disease designations to ART4, an experimental therapy for Alagille syndrome…
While different types of progressive familial intrahepatic cholestasis (PFIC) vary in their genetic cause and clinical profile, new medications like Bylvay (odevixibat) and Livmarli…
Problems in mitochondria, the cell’s powerhouses, may contribute to liver damage associated with cholestasis and represent a potential therapeutic target, a study showed. Deteriorating…
Regulators in the European Union (EU) have granted conditional approval to Rezdiffra (resmetirom) for some people with metabolic dysfunction-associated steatohepatitis (MASH), making it the first…
Chemomab Therapeutics has aligned with U.S. regulators on several aspects of the late-stage development of nebokitug, its candidate therapy for primary sclerosing cholangitis (PSC),…
High maternal levels of liver damage markers in the blood can predict poor fetal outcomes in twin pregnancies affected by intrahepatic cholestasis of pregnancy…
People with Alagille syndrome display different disease characteristics depending on whether the disease-causing mutation is located in the JAG1 gene or the NOTCH2 gene,…
An unreported mutation in the JAG1 gene was identified as the likely cause of Alagille syndrome in a 28-year-old woman, a case report from…